To study the effect of Paroxetine CR and Bupropion SR on cognition and levels of Interferon-gamma and Semaphorin 4D in patients with depression.
- Conditions
- Health Condition 1: null- Newly diagnosed patients of major depressive disorder (DSM-5)
- Registration Number
- CTRI/2018/05/013821
- Lead Sponsor
- CMS and GTB Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients of either sex with age between 18 -60 years.
2. Patient must meet DSM-5 (fifth edition of diagnostic and statistical manual of mental disorders) criteria MDD (single or recurrent episode).
3. Patient Health Questionnaire (PHQ-9) score of at least 15 at screening.
4. Patients/guardian willing to give written informed consent.
1. Patients of acute suicidal risk.
2. Lifetime DSM-5 diagnosis of dementia, schizophrenia, schizoaffective or bipolar diseases, post-traumatic disorder, obsessive compulsive disorder, anxiety, eating disorder.
3. Substance dependency.
4. Depression due to organic brain disease.
5. Pregnant and lactating women.
6. Any significant medical illness (hypertension, diabetes, epilepsy, asthma chronic kidney disease, hypothyroidism).
7. Patients/guardian not willing to give informed consent
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method